Trial reportJournal of digestive diseases2014
Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease.
Trial report in Journal of digestive diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease.World journal of gastroenterology · 2016Pooled it
- Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn's Disease: A Pilot Study.Biomedicines · 2023Article
- Effect of NUDT15 polymorphisms on early hematological safety of low-dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study.The Journal of dermatology · 2022Article
- Patients' Educational Program Could Improve Azathioprine Adherence in Crohn's Disease Maintenance Therapy.Gastroenterology research and practice · 2020Article
- Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.Medicine · 2018Observational
- Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study.Therapeutic advances in gastroenterology · 2017Article
- Rate and Predictors of Endoscopic Mucosal Healing in Biologic Naive Patients with Inflammatory Bowel Disease by Azathioprine Treatment: A Real World, 10 Years' Experience from a Single Centre in Turkey.Journal of gastrointestinal & digestive system · 2016Article
- Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID).Intestinal research · 2015Review
- Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?Current hepatology reports · 2015Article
- Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.World journal of gastroenterology · 2014Observational
- Implementation of the simple endoscopic activity score in crohn's disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate mucosal healing after 24-month low-dose azathioprine (AZA) treatment in Chinese patients with moderate small bowel Crohn's disease (CD).
methodsPatients with lesions mainly located at the ileum were screened by baseline multislice computed tomography enterography and anal-route double-balloon enteroscopy (DBE). They were naive to any immunomodulators and biological agents before the enrollment. Lesions from 150 cm of the terminal ileum proximal to ileocecal valve were assessed by DBE with the simple endoscopic score for CD (SES-CD) after 12 and 24 months of low-dose AZA treatment, respectively.
resultsThe average maximal tolerance dose of AZA was 61.8 ± 17.2 mg/day. The total rates of complete, near-complete, partial and no mucosal healing in 36 patients were 19.4%, 5.6%, 27.8% and 47.2% at month 12 and 30.6%, 25.0%, 33.3% and 11.1% at month 24, respectively. The baseline SES-CD (odds ratio [OR] 2.71, 95% confidence interval [CI] 1.11-6.63, P = 0.029) and duration of disease (OR 1.27, 95% CI 1.10-1.47, P = 0.001) were two relevant factors associated with the mucosal healing of patients with small bowel CD.
conclusionA 24-month low-dose AZA regimen as maintenance treatment in moderate small bowel CD could achieve a higher mucosal healing rate than that of 12-month treatment in Chinese patients, especially in those with duration of disease less than 12 months and a baseline SES-CD of 5 or 6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.